Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) Sees Large Drop in Short Interest

Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP - Get Free Report) saw a large decline in short interest in August. As of August 15th, there was short interest totaling 58,500 shares, a decline of 23.3% from the July 31st total of 76,300 shares. Based on an average daily trading volume, of 44,400 shares, the short-interest ratio is presently 1.3 days. Approximately 1.4% of the shares of the stock are sold short. Approximately 1.4% of the shares of the stock are sold short. Based on an average daily trading volume, of 44,400 shares, the short-interest ratio is presently 1.3 days.

Coeptis Therapeutics Price Performance

Shares of NASDAQ:COEP traded up $0.58 on Friday, reaching $13.01. 32,982 shares of the company traded hands, compared to its average volume of 43,875. Coeptis Therapeutics has a fifty-two week low of $2.31 and a fifty-two week high of $14.70. The company's 50 day moving average is $11.68 and its 200-day moving average is $10.14. The stock has a market capitalization of $62.71 million, a PE ratio of -2.24 and a beta of -0.57. The company has a debt-to-equity ratio of 0.02, a current ratio of 0.83 and a quick ratio of 0.83.

Coeptis Therapeutics (NASDAQ:COEP - Get Free Report) last announced its quarterly earnings data on Thursday, August 14th. The company reported ($1.17) EPS for the quarter. The firm had revenue of $0.20 million during the quarter.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen raised Coeptis Therapeutics from a "sell" rating to a "hold" rating in a research note on Thursday, May 22nd.

About Coeptis Therapeutics

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.